| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.019 | 0.8 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.8 |